Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MPT0B392 is an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,270.00 | |
50 mg | 6-8 weeks | $ 1,650.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | MPT0B392 is an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation. |
In vitro | MPT0B392 induces apoptosis in HL60 cancer cells[1]. MPT0B392 (0.1 μM for 6-48 hours; 0.01-0.1 μM for 24 and 48 hours) triggers cells arrest in the G2/M phase, followed by accumulation in subG1 phase in a concentration and time-dependent manner[1]. MPT0B392 (0.1 μM; 48 hours) increases the phosphorylation of Bcl-2, Mcl-1S and decreases in Mcl-1L[1]. |
In vivo | MPT0B392 shows relative potent anti-leukemia activity in a vivo xenograft model[1]. |
Molecular Weight | 404.44 |
Formula | C19H20N2O6S |
CAS No. | 1346169-92-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MPT0B392 1346169-92-3 Others MPT-0B392 MPT0B 392 MPT0B-392 inhibitor inhibit